semaglutide trizepatide Tirzepatide Linked to Better CV Outcomes Than Maintenance therapy on semaglutide or

Because GLP-1 medications suppress appetite, there's a higher risk of nutrient gaps

The barrier to entry is much lower than it once was. Clearly, peptides have entered the mainstream

The decision to use GLP-1 receptor agonists should be based on their licensed indications (diabetes or obesity management) rather than cholesterol lowering alone, with lipid improvements considered a beneficial additional effect within a comprehensive cardiovascular risk reduction strategy

While taking the drugs, she said, youre just not hungry. But once she stopped taking the medicine, she said, I have more cravings. Still, shes happy with where shes at now with her weight, after two years of Calibrates program

Crofford, Implications of glucocorticoid therapy in idiopathic inflammatory myopathies, Nat